Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Account Payables (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Change in Account Payables for 2 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 29.78% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.9 million through Dec 2025, down 218.55% year-over-year, with the annual reading at -$3.9 million for FY2025, 218.55% down from the prior year.
  • Change in Account Payables hit $1.3 million in Q4 2025 for Prelude Therapeutics, up from -$2.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $1.8 million in Q4 2024 to a low of -$2.4 million in Q3 2025.